The goal of the Mesothelioma Research Foundation of America (www.mesorfa.org) for Oncologists is to seek better treatment options for mesothelioma patients ultimately leading to a cure. With this goal in mind, the Oncologists' corner provides current mesothelioma information at the health professional level for practicing oncologists who have an interest in mesothelioma. For further information please contact the Chairman of our Medical Advisory Board, Dr. Parkash Gill, M.D. through our research foundation at (800) 909-6376, or email him a message here: Dr. Parkash Gill, M.D.
We also encourage a dialogue among Oncologists regarding alternative methods of therapy and the process of discovering a cure for mesothlioma. Use this link to find the interactions of Oncologist Researcher's Open Dialogue and Considerations
Dr. Gill currently has three (3) trials going for Mesothelioma cancer research. Each year he is treating more than 12 patients with Mesothelioma cancer. In 2013, Dr. Gill had five patients on one study of soluble ephB4 being treated at the Norris Cancer Center . These patients were referred from the University of Chicago , University of California at Davis, and several others.
Several institutions are collaborating with Dr. and his research projects, including:
His collaborations also are ongoing in Portugal and Switzerland .
This list provides a few important articles regarding Dr. Gill's research:
Molecular Pharmaceutics, American Chemical Society Publications
December 4, 2012
Accumulating evidence suggests that EphB4 plays key roles in cancer progression in numerous cancer types. In fact, therapies focusing on EphB4 have become potentially important components of various cancer treatment strategies. In this study, we developed near infrared fluorescence (NIRF) probes for EphB4 targeted imaging, a process which may predict whether an individual tumor would likely to respond to EphB4 targeted interventions, as well as monitor the therapeutic response.
Investigative Ophthalmology & Visual Science
January 2010, Vol. 51, No. 1
This study has demonstrated that sEphB4 inhibits PDGF-induced RPE cell attachment, proliferation, and migration. It was understood that EphB4 receptor (EphB4) and its ligand (EphrinB2) play an important role in the regulation of cell adhesion, growth, and migration. So, the purpose of this study was to determine the effects of EphB4 blockage and to establish its relevance to proliferative vitreoretinopathy (PVR). With our method the effect of sEphB4 on the phosphorylation of EphB4/EphrinB2 was demonstrated with the use of immunoprecipitation assays. The results showed sEphB4 blocked EphB4 and EphrinB2 phosphorylation in RPE cells in vitro.
Intellectual Property in Australia
December 7, 2012; Document AU2008226824
Use of EphB4 as a Diagnostic Marker and a Therapeutic Target for Ovarian Cancer related applications. Ovarian cancer is the second most common gynecologic cancer in women, with an estimated 22,220 new cases in the United States in the year 2005. The role of female sex hormones on the progression of ovarian cancer has also been studied. No effective screening tool exists for ovarian cancer and in over 80% cases, the diagnosis is not made until the disease is advanced, making treatment particular challenging. It is the goal of the present disclosure to provide agents and therapeutic treatments for inhibiting angiogenesis and tumor growth of ovarian cancer. The invention in certain aspects, the disclosure provides a method of treating ovarian cancer, the method comprising administering to a patient in need thereof an effective amount of an EphB4 inhibitor. In certain embodiments, the EphB4 inhibitor is an antibody or antigen binding fragment thereof.
Intellectual Property in Australia
December 7, 2012; Document AU2005286662
In certain embodiments, this present invention provides polypeptide compositions, in cluding compositions a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis associated diseases.
There have been significant improvements creating new options for patients with Mesothelioma lung cancer. This video presents the new options for a patient to be aware of and consider. This news release video, created by Med Page Today, is about Oncology and Lung Cancer has been shared on YouTube by the Mesothelioma Research Foundation of America.
Allessandro Marinaccio, et. al.
Epidemiology Unit, Department of Occupational Medicine, ISPESL (Italian National Institute for Occupational Safety and Prevention)
The objective of this study is to present data taken from the Italian National Mesothelioma Register (ReNaM). This is compelling because the epidemiology of extrapleural malignant mesothelioma is rarely discussed and the risk of misdiagnosis and the very low incidence complicate the picture.
The rarity of the disease, the low specificity of diagnosis and difficulties in identifying the modalities of asbestos exposure call for caution in discussing aetiological factors other than asbestos.
Eiji Yano, Xiaorong Wang, Mianzhen Wang, et al.
Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan.
The objective is to confirm the association between exposure to chrysotile asbestos and lung cancer risk and to demonstrate the combined effect of smoking and asbestos exposure. Our method includes a case-control study of 1139 asbestos workers that identified 41 male lung cancer cases with each case matched by age with five controls. Workers in seven workshops were categorized into subgroups, and conditional logistic regression was applied to estimate the odds ratio for lung cancer risk associated with the different exposure levels.
The results of this study confirm a strong association between exposure to chrysolite asbestos and lung cancer risk, and support an interactive effect of asbestos exposure and smoking which is more than additive.
Sato A, Torii I, Okamura Y, Yamamoto T, Nishigami T, Kataoka TR, Song M, Hasegawa S, Nakano T, Kamei T, Tsujimura T.
Department of Pathology, Hyogo College of Medicine, Hyogo, Japan.
Malignant pleural mesothelioma is a refractory tumor with poor prognosis associated with asbestos exposure. Pleural effusion is frequently observed in patients with malignant pleural mesothelioma, and cytological analysis is effective to detect malignant pleural mesothelioma. However, cytological discrimination between malignant pleural mesothelioma and reactive mesothelium is often difficult. Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer. In this study, to evaluate the diagnostic utility of CD146 for discrimination between malignant pleural mesothelioma and reactive mesothelium, we examined immunocytochemical expression of CD146 in malignant pleural mesothelioma and reactive mesothelium using two clones of CD146 antibody, OJ79 and EPR3208, on smear specimens of effusion fluids. Immunocytochemical stains were semiquantitatively scored on the basis of immunostaining intensity (0, negative; 1, weak positive; 2, moderate positive; and 3, strong positive).
CD146 expression was detected in 15 of 16 malignant pleural mesothelioma with median immunostaining score of 3 by OJ79, and in 19 of 21 malignant pleural mesothelioma with median immunostaining score of 2 by EPR3208. Strong immunoreactivity of CD146 was observed at the apposing surfaces of cell-cell interactions on the plasma membrane of mesothelioma cells. In addition, one OJ79-negative case of malignant pleural mesothelioma was positive for CD146 by EPR3208 and two EPR3208-negative cases of malignant pleural mesothelioma were CD146 positive by OJ79, showing that all 23 malignant pleural mesothelioma cases were positive for CD146 by either OJ79 or EPR3208. On the other hand, CD146 expression was undetectable in all reactive mesothelium cases by OJ79 and EPR3208. The sensitivity of OJ79 and EPR3208 was 94 and 90%, respectively, and the specificity was 100% for both clones.
We propose that CD146 is a sensitive and specific immunocytochemical marker enabling differential diagnosis of malignant pleural mesothelioma from reactive mesothelium.Modern Pathology advance online publication, 23 July 2010; doi:10.1038/modpathol.2010.134.
Eiji Yano, Xiaorong Wang, Mianzhen Wang, Hong Qiu, Zhiming Wang
Department of Hygiene and Public Health, Teikyo University of Medicine, Tokyo, Japan.
The objective was to confirm the association between exposure to chrysotile asbestos and lung cancer risk and to demonstrate the combined effect of smoking and asbestos exposure. The results confirm the strong association between exposure to chrysotile asbestos and lung cancer risk, and support an interactive effect of asbestos exposure an smoking which is more than additive.
Message presented to the Forty-sixth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 25-27, 2010
Malignant pleural mesothelioma is an aggressive cancer disease known to be caused by asbestos exposure. Men have a higher incidence of mesothelioma cancer than women do to a likely increase of occupational asbestos exposure among men. However, women appear to experience better long-term survival from the disease. This report brings the results of a research study on 702 patients in which women demonstrated a survival advantage. The findings support an aggressive approach to treating malignant pleural mesothelioma.
Dr. Parkash S. Gill --
USC Norris Comprehensive Cancer Center
Clin Cancer Res 2005;11(12) June 15, 2005
Lori Oliwenstien -- USC Health Magazine
In addition to blocking an enzyme responsible for tumor growth and metastasis, the drug VEGLIN appears to slow the growth of the cancer cells themselves. The success of Dr. Alexandra M. Levine, M.D. distinguished Professor of Medicine, chief of hematology at the Keck School of Medicine and the medical director of the USC/Norris Cancer Hospital has treated 37 patients with various types of cancers with the Veglin. "... the results are quite impressive, and we are very pleased so far".
As a professional Oncologist, you will find here some of Dr. Gill's recent technical writing that causes us all to have a great hope.
TECHNICAL DOCUMENT (revision - July 2004):
A Phase II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin) in the Treatment of Relapsed Malignant Mesothelioma
The following are email conversations among practicing Oncologists and researchers regarding studies, therapy, and their search for a cure to mesothelioma cancer.
From: Vadim Shapoval [mailto:firstname.lastname@example.org]
Sent: Tuesday, October 12, 2010 3:55 AM
Subject: American Cancer Society & Ferromagnetic theory of cancer
Dear Elizabeth Paul,
American Cancer Society & Ferromagnetic theory of cancer
Each year, the American Cancer Society (ACS) estimates the number of new cancer cases and deaths expected in the United States in the current year. A total of 1,399,790 new cancer cases and 564,830 deaths from cancer (1,500 deaths per day) are expected in the United States in 2006. http://caonline.amcancersoc.org/cgi/content/full/56/2/106 Cancer is a major public health problem in the United States and other developed countries. According to the ACS, 565,650 people died of cancer in the U.S. in 2008 http://www.tutuz.com/?p=1235 http://dying.lovetoknow.com/Cancer_Death_Statistics For 2010, American Cancer Society predicts 1,529,560 new cancer cases (789,620 in men and 739,940 in women) and 569,490 cancer deaths (299,200 in men and 270,290 in women). http://health.msn.com/health-topics/breast-cancer/articlepage.aspx?cp-documentid=100261010
The ferromagnetic theory of cancer is theory-2006. According to this theory, American cancer patients must receive: 1) Slow blood loss (hemoglobin control); 2) Non-iron and anti-iron (goat's milk, etc.) nutrition; 3) ‘Anti-iron injections for tumors and big metastases'. H2S-water or/and suspension ‘sulfur + water' or/and suspension ‘sulfur + olive-oil' ARE anti-iron anti-tumor anti-bacterial anti-virus substances. These substances can convert tumors to non-dangerous infiltrations. Overdoses can destroy any cancer patient. Adequate anti-iron doses can destroy any tumor and metastases. Modern ACS's chemotherapy, radiation therapy and immunotherapy are bad therapies. American Cancer Society cannot understand clinical aspects of the ferromagnetic theory-2006 of cancer.
In my opinion, ACS's War Against Cancer is a false forged war. According to iron logic and iron-cancer researches of various American scientific organizations and groups, ACS will receive great financial and ambitious pains because the United States will beat oncopathologies and AIDS by means of accurate non-complicated anti-iron methods soon.
Vadim I. Shapoval
Eugene D. Weinberg & Ferromagnetic theory of cancer http://www.tutuz.com/?p=1419
Oxford Journal CARCINOGENESIS http://www.tutuz.com/?p=1380
Restricting the Use of Iron to Tumors - Novel Cancer Treatment-Mayo Clinic http://www.tutuz.com/?p=1351
Harold Varmus, Nobel Committee, President Obama & Ferromagnetic theory of cancer (Iron Conception) http://www.tutuz.com/?p=1278
(1148, 1197, 1315, 1305, 1235, 1155, 1241, 1202, 1171, 1249, 1166) http://ferromcancer.wordpress.com/
While this blog post is interesting and I was brought here by my keyword search on cures to mesothelioma using Ferromagnetic theory of cancer, I used the search feature of the browser to not find any mention of mesothelioma disease. We did find one other link reference that methioned mesothelioma cancer with Ferromagnetic theory of cancer. We want to discover just how much the iron theory contributes to the understanding and hope for a cure for one who gets lung cancer from exposure to asbestos which caused the mesothelioma. How can your studies be integrated with the hope we found in the cancer studies at the Mesothelioma Research Foundation of America? Their Oncologist Dr. Parkash S. Gill is a professor of Medicine and Pathology and leads the research team. Dr. Gill would welcome anyone's dialogue and questions regarding mesothelioma cancer from asbestos exposure and research finding a cure. How can Ferromagnetic theory contribute to find a cure for mesothelioma cancer?
Please contact the Chairman of our Medical Advisory Board, Dr. Parkash Gill, M.D. through our research foundation at (800) 909-6376, or email him a message here: Dr. Parkash Gill, M.D.
For questions related to the foundation and to make contributions please contact:
(800) 909-Meso (6376)
3011 Townsgate Rd, Suite 450
Westlake Village, CA 91361
For more information and other questions contact:
©2016 Mesothelioma Research Foundation Of America